- Home
- TSI vs BMEA Comparison
TSI vs BMEA Comparison
Compare TSI & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSI
- BMEA
- Stock Information
- Founded
- TSI 1987
- BMEA 2017
- Country
- TSI United States
- BMEA United States
- Employees
- TSI N/A
- BMEA N/A
- Industry
- TSI Investment Managers
- BMEA Biotechnology: Pharmaceutical Preparations
- Sector
- TSI Finance
- BMEA Health Care
- Exchange
- TSI Nasdaq
- BMEA Nasdaq
- Market Cap
- TSI 237.0M
- BMEA 275.6M
- IPO Year
- TSI N/A
- BMEA 2021
- Fundamental
- Price
- TSI $4.96
- BMEA $6.53
- Analyst Decision
- TSI
- BMEA Buy
- Analyst Count
- TSI 0
- BMEA 13
- Target Price
- TSI N/A
- BMEA $37.25
- AVG Volume (30 Days)
- TSI 106.8K
- BMEA 817.8K
- Earning Date
- TSI 01-01-0001
- BMEA 10-29-2024
- Dividend Yield
- TSI 7.46%
- BMEA N/A
- EPS Growth
- TSI N/A
- BMEA N/A
- EPS
- TSI N/A
- BMEA N/A
- Revenue
- TSI N/A
- BMEA N/A
- Revenue This Year
- TSI N/A
- BMEA N/A
- Revenue Next Year
- TSI N/A
- BMEA N/A
- P/E Ratio
- TSI N/A
- BMEA N/A
- Revenue Growth
- TSI N/A
- BMEA N/A
- 52 Week Low
- TSI $4.48
- BMEA $3.61
- 52 Week High
- TSI $4.87
- BMEA $22.74
- Technical
- Relative Strength Index (RSI)
- TSI 41.31
- BMEA 23.64
- Support Level
- TSI $4.91
- BMEA $8.60
- Resistance Level
- TSI $5.11
- BMEA $9.34
- Average True Range (ATR)
- TSI 0.06
- BMEA 0.79
- MACD
- TSI -0.01
- BMEA -0.40
- Stochastic Oscillator
- TSI 21.43
- BMEA 0.82
About TSI TCW Strategic Income Fund Inc.
Tcw Strategic Income Fund Inc operates as a closed-end management investment company. Its investment objective is to seek a total return comprised of current income and capital appreciation by investing in a wide range of securities. The company invests in a range of industries, such as airlines, banks, beverages, biotechnology, chemicals, computers, diversified financial services, entertainment, and others.
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.